About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

NM-002

Company: 9 Meters Biopharma, Inc.
Mechanism: Mechanism not yet reported
Route: Route not yet reported
Recruiting trials: None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details

Completed NCT NCT02500511

Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up Study

JN-International Medical Corporation 50 participants Est. completion 2015-09 1 site

Other conditions: Meningococcal Meningitis, Meningococcal Infections
View official trial listing →
Status unknown NCT NCT04379856

Proof of Concept Study in Patients With Short Bowel Syndrome

Not yet reported, Not yet reported 9 Meters Biopharma, Inc. 12 participants Est. completion 2020-12-31 1 site Stand-alone

Other conditions: Short Bowel Syndrome
View official trial listing →

Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

ClinicalTrials.gov — NCT04379856

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.